OHSONG PHARM Co., Ltd. (CEO, Young-Joong Kim) is set to supply new products to the Japanese pharmaceutical market.

Recently, OHSONG PHARM signed an agreement with N company, a major Japanese pharmaceutical company, to develop a hyaluronic acid injection. The sample production for this project began in late July.

So far, OHSONG PHARM has been well known as the No. 1 penicillin exporter to Japan. However, the development and sales of hyaluronic acid products have expanded its product lineup, allowing the company to offer new products beyond just penicillin.

The sodium hyaluronate product works by forming a film on cartilage tissue in the arthritis area, aiding in the healing of cartilage through lubrication and shock absorption. This product is steadily growing in the arthritis therapeutic market. In addition, the market response is expected to improve even more with  the development of prefilled syringe formulations, which offer enhanced usability.

The sample production of hyaluronic acid products will begin in the second half of 2019, and it is expected to be officially released in Japan 2021.

OHSONG PHARM has been steadily accumulating not only experience but also know-how in the Japanese pharmaceutical market for over 10 years. Since the establishment of its Japanese subsidiary, Brio Pharma, in 2017, the company has become even more concentrated and targeted in its approach to the Japanese pharmaceutical market.

OHSONG PHARM will continue to introduce differentiated pharmaceuticals to the Japanese market, strengthening its position as a leading company in the Korean pharmaceutical bio industry in Japan.